Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 10/20 | 0.49 |
| ▸ | PNP | P00491 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21127785 | 0.83 | HPRT1 (0.48) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL1992701 | 0.78 | HPRT1 (0.54) | HPRT1PNPALDH1A1 | |
| SCHEMBL7405149 | 0.77 | HPRT1 (0.47) | HPRT1PNPADORA3LMNAALDH1A1 | |
| SCHEMBL22381490 | 0.76 | HPRT1 (0.63) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL19569930 | 0.76 | XDH (0.55) | HPRT1PNPMEN1KMT2A | |
| SCHEMBL23228187 | 0.74 | HPRT1 (0.45) | HPRT1PNPADORA3 | |
| SCHEMBL21417467 | 0.74 | PNP (0.46) | HPRT1PNPADORA3LMNAMEN1 | |
| SCHEMBL21943254 | 0.73 | HPRT1 (0.44) | HPRT1PNPADORA3 | |
| SCHEMBL21362204 | 0.73 | HPRT1 (0.51) | HPRT1PNPLMNAMEN1KMT2A | |
| SCHEMBL8791177 | 0.73 | HPRT1 (0.51) | HPRT1PNPLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11203610-B2 | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2021-12-21 | — | — | US | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | HPRT1 248/4885PNP 174/4885ADORA3 579/4885 |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | HPRT1 139/4885PNP 138/4885ADORA3 648/4885 |
| US-10980825-B2 | Cyclic dinucleotide | STING1, CGAS, MAVS | HPRT1 139/4885PNP 138/4885ADORA3 648/4885 |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | HPRT1 139/4885PNP 138/4885ADORA3 648/4885 |
| US-11203610-B2 | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein | STING1, CGAS, IRF3 | HPRT1 830/4885PNP 446/4885ADORA3 1062/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | HPRT1 274/4885PNP 462/4885ADORA3 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.